{"data":[{"accessionNo":"0001104659-26-097255","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":"H0036K147","securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2026-06-30","reportingPerson":"Wilmot B. Harkey","reportingCik":null,"personType":"HC","sharesOwned":12326184,"percentOfClass":9.69,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-097255","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":"H0036K147","securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2026-06-30","reportingPerson":"Nantahala Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":12326184,"percentOfClass":9.69,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-097255","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":"H0036K147","securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2026-06-30","reportingPerson":"Daniel Mack","reportingCik":null,"personType":"HC","sharesOwned":12326184,"percentOfClass":9.69,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0002012383-26-002147","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001771910","issuerName":"ADC THERAPEUTICS SA","ticker":"ADCT","cusip":"H0036K147","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":6857815,"percentOfClass":5.4,"filedAt":"2026-07-27","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-048804","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":"H0036K147","securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2026-04-20","reportingPerson":"Redmile Group, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":12717487,"percentOfClass":9.9,"filedAt":"2026-04-24","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-048804","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":"H0036K147","securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2026-04-20","reportingPerson":"Jeremy C. Green","reportingCik":null,"personType":"HC,IN","sharesOwned":12717487,"percentOfClass":9.9,"filedAt":"2026-04-24","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-048804","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":"H0036K147","securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2026-04-20","reportingPerson":"RedCo II Offshore SPV LLC","reportingCik":null,"personType":"FI,OO","sharesOwned":7780431,"percentOfClass":6.1,"filedAt":"2026-04-24","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-048804","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":"H0036K147","securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2026-04-20","reportingPerson":"RedCo II Master Fund, L.P.","reportingCik":null,"personType":"PN,FI","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-04-24","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-040084","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":"H0036K147","securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2026-04-06","reportingPerson":"Redmile Group, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":12692841,"percentOfClass":9.9,"filedAt":"2026-04-06","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-040084","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":"H0036K147","securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2026-04-06","reportingPerson":"Jeremy C. Green","reportingCik":null,"personType":"HC,IN","sharesOwned":12692841,"percentOfClass":9.9,"filedAt":"2026-04-06","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-040084","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":"H0036K147","securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2026-04-06","reportingPerson":"RedCo II Master Fund, L.P.","reportingCik":null,"personType":"PN,FI","sharesOwned":10276407,"percentOfClass":8.1,"filedAt":"2026-04-06","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-016431","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2025-12-31","reportingPerson":"Redmile Group, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":15666731,"percentOfClass":12.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-016431","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2025-12-31","reportingPerson":"Jeremy C. Green","reportingCik":null,"personType":"HC,IN","sharesOwned":15666731,"percentOfClass":12.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-016431","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2025-12-31","reportingPerson":"RedCo II Master Fund, L.P.","reportingCik":null,"personType":"PN,FI","sharesOwned":13145712,"percentOfClass":10.6,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001193125-26-054764","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares, par value CHF $0.08 per share","eventDate":"2025-10-27","reportingPerson":"Chen Yu","reportingCik":null,"personType":"IN","sharesOwned":11390175,"percentOfClass":9.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001193125-26-054764","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares, par value CHF $0.08 per share","eventDate":"2025-10-27","reportingPerson":"TCG Crossover GP II, LLC","reportingCik":null,"personType":"OO","sharesOwned":11390175,"percentOfClass":9.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001193125-26-054764","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares, par value CHF $0.08 per share","eventDate":"2025-10-27","reportingPerson":"TCG Crossover Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":11390175,"percentOfClass":9.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0000902664-26-001151","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2025-12-31","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":5014617,"percentOfClass":4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0000902664-26-001151","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2025-12-31","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":5014617,"percentOfClass":4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0000902664-26-001151","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2025-12-31","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":5014617,"percentOfClass":4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0000947871-26-000186","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2025-12-31","reportingPerson":"ORBIMED CAPITAL LLC","reportingCik":null,"personType":"IA","sharesOwned":3230797,"percentOfClass":2.6,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0000947871-26-000186","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares, par value CHF 0.08 per share","eventDate":"2025-12-31","reportingPerson":"ORBIMED ADVISORS LLC","reportingCik":null,"personType":"IA","sharesOwned":2592057,"percentOfClass":2.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-015265","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001771910","issuerName":"ADC THERAPEUTICS SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-12-31","reportingPerson":"W. Lawrence Hawkins","reportingCik":null,"personType":"HC,IN","sharesOwned":8477338,"percentOfClass":6.8,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-015265","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001771910","issuerName":"ADC THERAPEUTICS SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-12-31","reportingPerson":"Prosight Management, LP","reportingCik":null,"personType":"IA","sharesOwned":8477338,"percentOfClass":6.8,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-015265","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001771910","issuerName":"ADC THERAPEUTICS SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-12-31","reportingPerson":"Prosight Partners, LLC","reportingCik":null,"personType":"OO","sharesOwned":8477338,"percentOfClass":6.8,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-015265","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001771910","issuerName":"ADC THERAPEUTICS SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-12-31","reportingPerson":"Prosight Plus Fund, LP","reportingCik":null,"personType":"PN","sharesOwned":1849305,"percentOfClass":1.5,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-26-015265","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001771910","issuerName":"ADC THERAPEUTICS SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-12-31","reportingPerson":"Prosight Fund, LP","reportingCik":null,"personType":"PN","sharesOwned":402286,"percentOfClass":0.3,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-25-111601","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-09-30","reportingPerson":"Prosight Management, LP","reportingCik":null,"personType":"IA","sharesOwned":7195374,"percentOfClass":5.8,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-25-111601","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-09-30","reportingPerson":"W. Lawrence Hawkins","reportingCik":null,"personType":"HC,IN","sharesOwned":7195374,"percentOfClass":5.8,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-25-111601","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-09-30","reportingPerson":"Prosight Partners, LLC","reportingCik":null,"personType":"OO","sharesOwned":7195374,"percentOfClass":5.8,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-25-111601","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-09-30","reportingPerson":"Prosight Plus Fund, LP","reportingCik":null,"personType":"PN","sharesOwned":1586895,"percentOfClass":1.3,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001104659-25-111601","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-09-30","reportingPerson":"Prosight Fund, LP","reportingCik":null,"personType":"PN","sharesOwned":350415,"percentOfClass":0.3,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001140361-25-040534","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-09-30","reportingPerson":"Oaktree Fund Administration, LLC","reportingCik":null,"personType":"OO","sharesOwned":4673441,"percentOfClass":4.14,"filedAt":"2025-11-05","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001140361-25-040534","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-09-30","reportingPerson":"Oaktree Capital Holdings, LLC","reportingCik":null,"personType":"OO","sharesOwned":4673441,"percentOfClass":4.14,"filedAt":"2025-11-05","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001140361-25-040534","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-09-30","reportingPerson":"Oaktree Capital Group Holdings GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":4673441,"percentOfClass":4.14,"filedAt":"2025-11-05","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001140361-25-040534","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-09-30","reportingPerson":"Brookfield Asset Management ULC","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-11-05","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001140361-25-040534","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-09-30","reportingPerson":"Brookfield Corporation","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-11-05","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001140361-25-040534","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-09-30","reportingPerson":"Brookfield Asset Management, Ltd.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-11-05","canonicalUrl":"https://xoomar.com/markets/stocks/adct"},{"accessionNo":"0001140361-25-040534","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001771910","issuerName":"ADC Therapeutics SA","ticker":"ADCT","cusip":null,"securityClass":"Common Shares","eventDate":"2025-09-30","reportingPerson":"BAM Partners Trust","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-11-05","canonicalUrl":"https://xoomar.com/markets/stocks/adct"}],"updatedAt":"2026-10-24T19:12:31.077Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/adct","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}